Humanized anti-CD40 antibodies and methods of administering thereof
The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
1. A humanized anti-CD40 antibody or a CD40-binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 21, and wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 23.
2. The antibody or CD40-binding portion thereof of claim 1 , wherein the dissociation constant (K D ) of the antibody, or antigen-binding portion thereof, is less than about 1×10 −9 M.
3. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof is selected from the group consisting of: (a) a whole immunoglobulin molecule; (b) an scFv; (c) a Fab fragment; (d) an F(ab′) 2 ; and (e) a disulfide linked Fv.
4. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof comprises at least one constant domain selected from the group consisting of: a) an IgG constant domain; and (b) an IgA constant domain.
5. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof comprises at least one human constant domain.
6. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof binds to CD40 extracellular domain.
7. The antibody or CD40-binding portion thereof of claim 1 , wherein the CD40 is human or rhesus CD40.
8. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof blocks B lymphocyte activation by CD154-expressing Jurkat cells in vitro.
9. The antibody or CD40-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof inhibits B lymphocyte CD23, CD80, or CD86 expression.
10. A composition comprising the antibody or CD40-binding portion thereof of claim 1 .
11. An isolated polypeptide comprising the antibody or CD40-binding portion thereof of claim 1 .
12. A method of suppressing an immune system in a subject, comprising the step of administering to the subject an effective amount of the antibody or CD40-binding portion thereof of claim 1 .
13. A method of treating or treating prophylactically transplant rejection, or increasing the duration of time before transplant rejection occurs, in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of the antibody or CD40-binding portion thereof of claim 1 .
14. The method of claim 12 , wherein the subject has received, or is in need of, an organ transplantation or a tissue transplantation.
15. The method of claim 14 , wherein the organ is selected from the group consisting of heart, kidney, lung, liver, pancreas, intestine, and thymus, or a portion thereof.
16. The method of claim 14 , wherein the tissue is bone, tendon, cornea, skin, heart valve, vein, or bone marrow.
17. The method of claim 12 , wherein the subject is a human.
18. The method of claim 12 , wherein the administration is parenteral, intravenous, subcutaneous, intramuscular, transdermal, oral, topical, intrathecal, or local.
19. A method of treating or treating prophylactically graft-versus-host disease in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of the antibody or CD40-binding portion thereof of claim 1 .
20. A method of blocking CD40 interaction with CD154 in a subject, the method comprising the step of administering to the subject an effective amount of the antibody or CD40-binding portion thereof of claim 1 .
21. A method of inhibiting or reducing growth and/or differentiation of CD40-expressing cells in a subject, the method comprising the step of administering to the subject an effective amount of the antibody or CD40-binding portion thereof of claim 1 .
22. The method of claim 20 , wherein the subject has an autoimmune disease or an inflammatory disorder.
23. The method of claim 21 , wherein the subject has a CD40-associated disorder.
24. The method of claim 23 , wherein the CD40-associated disorder is an autoimmune disease or an inflammatory disorder.